Stanley-Laman Group’s 10x Genomics TXG Stock Holding History

Stanley-Laman Group’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-66,643	Closed	-$9.93M	–	311
2021 Q4	$9.93M	Buy	+66,643	New	+$10.2M	1.17%	22

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stanley-Laman Group's TXG Position: Q1 2022 in Review

Stanley-Laman Group sold out of 10x Genomics (TXG) in Q1 2022, closing a stake of 66,643 shares — an estimated $9.93M sold.

Stanley-Laman Group first reported a position in TXG in Q4 2021 and held it in 1 quarter. The position peaked at $9.93M in Q4 2021. 314 funds tracked by Wall St. Rank hold TXG as of Q1 2022.

Stanley-Laman Group reported no remaining 10x Genomics position as of Q1 2022 after selling out during the quarter.
Stanley-Laman Group sold 66,643 10x Genomics shares in Q1 2022, an estimated $9.93M.
Stanley-Laman Group first reported a position in 10x Genomics in Q4 2021 and held it in 1 quarter.
Stanley-Laman Group's 10x Genomics position peaked at $9.93M in Q4 2021.
314 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2022.

Based on Stanley-Laman Group's 13F filing for Q1 2022, filed 21 Apr 2022.